PUBLISHER: The Business Research Company | PRODUCT CODE: 1751160
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751160
A vasopressor is a drug that constricts blood vessels, raising blood pressure by enhancing vascular tone. It is primarily used in critical care to manage severe hypotension and ensure adequate blood flow to vital organs. By stabilizing circulation, vasopressors help prevent life-threatening complications in critically ill patients.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of vasopressors include catecholamines, non-catecholamines, and vasopressin. Catecholamines are hormones such as dopamine, norepinephrine, and epinephrine, produced by the adrenal glands and involved in the body's stress response. These drugs can be administered through various routes, such as intravenous (IV), intraosseous, and inhalational methods, for applications such as managing hypotension, treating septic shock, supporting cardiogenic shock, post-surgical management, and others. They are used in various settings, including hospitals, ambulatory surgical centers, emergency medical services, and home care.
The vasopressor market research report is one of a series of new reports from The Business Research Company that provides vasopressor market statistics, including vasopressor industry global market size, regional shares, competitors with a vasopressor market share, detailed vasopressor market segments, market trends and opportunities, and any further data you may need to thrive in the vasopressor industry. This vasopressor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The vasopressor market size has grown strongly in recent years. It will grow from$3.51 billion in 2024 to $3.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be attributed to several factors, including the increasing geriatric population, rising healthcare expenditure, expanding government initiatives, a growing number of hospitals, and the increasing prevalence of cardiovascular diseases.
The vasopressor market size is expected to see strong growth in the next few years. It will grow to$4.92 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth during the forecast period can be attributed to several factors, including the rising incidence of hypertension, greater adoption of advanced sepsis management guidelines, increasing investments in critical care technologies, the growing prevalence of septic shock, and a rising demand for personalized critical care. Key trends during this period include advancements in drug formulations, the development of tailored therapies, technological innovations in smart infusion pumps, the integration of telemedicine with vasopressor therapy, and innovations in biodegradable vasopressor implants.
The growing prevalence of heart diseases is anticipated to fuel the expansion of the vasopressor market in the coming years. Heart diseases encompass a range of conditions that affect the heart's structure and functionality, including coronary artery disease, arrhythmias, heart failure, and congenital heart defects. With the rise in sedentary lifestyles, obesity and poor cardiovascular health are becoming more common, substantially elevating the risk of heart-related conditions. Vasopressors aid in the treatment of heart disease by constricting blood vessels, which helps raise blood pressure and enhance blood flow to vital organs, thus supporting cardiovascular function during critical states. For example, in December 2023, the Australian Institute of Health and Welfare, a government agency in Australia, reported that doctor-certified deaths due to coronary heart disease (CHD) rose from 14,100 in 2021 to 14,900 in 2022. Consequently, the increasing rate of heart disease is contributing to the growth of the vasopressor market.
Leading players in the vasopressor market are concentrating on the development of advanced solutions such as intravenous (IV) vasopressors to better regulate blood pressure and improve patient outcomes. IV vasopressors are employed to constrict blood vessels and raise blood pressure in patients suffering from severe hypotension or shock, thereby ensuring sufficient blood flow to essential organs. For instance, in June 2023, Fresenius Kabi AG, a pharmaceutical company based in Germany, introduced Vasopressin Injection, USP, a generic version of Vasostrict, in the U.S. market, broadening its critical care product lineup. This drug is specifically indicated for adults experiencing vasodilatory shock who remain hypotensive after receiving fluids and catecholamines. It comes in a single-dose vial containing 20 units per 1 mL.
In April 2024, Endo Inc., a pharmaceutical company based in the United States, acquired assets from Endo International plc (EIP) for an undisclosed amount. Through this acquisition, Endo Inc. aims to enhance its financial stability, expand its product range, foster innovation, gain operational efficiencies, and strategically position itself for future growth in the pharmaceutical sector. Endo International plc, headquartered in Ireland, is a pharmaceutical firm known for manufacturing and distributing vasopressin.
Major players in the vasopressor market are Pfizer Inc., Merck And Co Inc., Novartis AG, Baxter International Inc., Fresenius Kabi AG, Bauch & Lomb Incorporated, Dr. Reddy's Laboratories Limited, Hikma Pharmaceuticals PLC, Endo Inc., Amphastar Pharmaceuticals Inc., American Regent Incorporated, Celon Laboratories Ltd., Athenex Inc., Sagent Pharmaceuticals Inc., Civica Rx, Eton Pharmaceuticals Inc., Amomed Pharma GmbH, Health Biotech Limited, Samarth Life Sciences Pvt. Ltd, and Pace Biotech Limited.
North America was the largest region in the vasopressor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vasopressor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vasopressor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vasopressor market consists of sales of norepinephrine, epinephrine, dopamine, and phenylephrine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vasopressor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vasopressor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for vasopressor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vasopressor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.